Syros Pharmaceuticals is a biopharmaceutical company that discovers and develops medicines that control the expression of genes with the aim of treating cancer and other serious diseases. The Company has built a proprietary platform that identifies crucial genes that become dysregulated in diseased cells in order to create medicines that return cells to a non-diseased state. The Company’s platform will allow it to create a pipeline of gene control medicines that will provide a benefit for currently underserved genomically defined patients. The Company’s lead program, SY-1425 (tamibarotene), is an orally-administered RARα agonist, which is an already approved agent in Japan as Amnolake indicated for APL. SY-1425 is in U.S. Phase II development for the treatment of newly diagnosed acute myeloid leukemia (AML) in combination with azacitidine. The Company’s second candidate, SY-1365, is focused on the treatment of subsets of cancers that depend on constant expression of certain transcription factors for their growth and survival. Through the program, the Company has generated selective small molecule CDK7 inhibitors that demonstrated significant anti-tumor activity and preferentially killed cancer cells over healthy cells within in vivo models of several aggressive cancers, such as breast, ovarian and small cell lung.